SG10202010180YA - Dihydropyrimidine compound and preparation method and use thereof - Google Patents
Dihydropyrimidine compound and preparation method and use thereofInfo
- Publication number
- SG10202010180YA SG10202010180YA SG10202010180YA SG10202010180YA SG10202010180YA SG 10202010180Y A SG10202010180Y A SG 10202010180YA SG 10202010180Y A SG10202010180Y A SG 10202010180YA SG 10202010180Y A SG10202010180Y A SG 10202010180YA SG 10202010180Y A SG10202010180Y A SG 10202010180YA
- Authority
- SG
- Singapore
- Prior art keywords
- preparation
- dihydropyrimidine compound
- dihydropyrimidine
- compound
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5355—Non-condensed oxazines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201611015150 | 2016-11-18 | ||
| CN201710328659 | 2017-05-11 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG10202010180YA true SG10202010180YA (en) | 2020-11-27 |
Family
ID=62145967
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10202010180YA SG10202010180YA (en) | 2016-11-18 | 2017-11-09 | Dihydropyrimidine compound and preparation method and use thereof |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US10696669B2 (en) |
| EP (1) | EP3508483B1 (en) |
| JP (1) | JP7139568B2 (en) |
| KR (1) | KR102496508B1 (en) |
| CN (1) | CN109790145B (en) |
| AU (1) | AU2017359773B2 (en) |
| BR (1) | BR112019005205A2 (en) |
| CA (1) | CA3037218A1 (en) |
| ES (1) | ES2901401T3 (en) |
| IL (1) | IL266345A (en) |
| MX (1) | MX2019005119A (en) |
| MY (1) | MY194471A (en) |
| PH (1) | PH12019550039A1 (en) |
| PL (1) | PL3508483T3 (en) |
| SG (1) | SG10202010180YA (en) |
| WO (1) | WO2018090862A1 (en) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108329308B (en) * | 2018-05-16 | 2022-11-01 | 四川科伦博泰生物医药股份有限公司 | Solid form of dihydropyrimidine compound and preparation method thereof |
| US20220249647A1 (en) | 2019-06-18 | 2022-08-11 | Janssen Sciences Ireland Unlimited Company | Combination of hepatitis b virus (hbv) vaccines and dihydropyrimidine derivatives as capsid assembly modulators |
| CN112575389B (en) * | 2019-09-30 | 2023-09-19 | 成都先导药物开发股份有限公司 | Liquid chromatography purification method of DNA coding compound library |
| CN116888118A (en) | 2021-02-05 | 2023-10-13 | 和博医药有限公司 | Phenyl dihydropyrimidine compound and application thereof |
| CN114853761A (en) * | 2021-02-05 | 2022-08-05 | 刘沛 | Bifunctional derivative containing dihydropyrimidine and application thereof |
| CN113512035B (en) * | 2021-04-26 | 2023-11-24 | 山东大学 | Dihydropyrimidine-pomalidomide conjugate, and preparation method and application thereof |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10013126A1 (en) | 2000-03-17 | 2001-09-20 | Bayer Ag | New 6-aminoalkyl-dihydropyrimidine-5-carboxylate ester derivatives, useful as antiviral agents having strong activity against hepatitis B virus and low cytotoxicity |
| CN101225084A (en) | 2007-01-16 | 2008-07-23 | 北京摩力克科技有限公司 | Dihydropyrimidine compound and use thereof in preparation of medicine treating and preventing virus diseases |
| WO2010069147A1 (en) | 2008-12-17 | 2010-06-24 | 张中能 | Dihydropyrimidine derivatives, compositions thereof and their use |
| CN101575318B (en) | 2009-06-25 | 2012-02-08 | 中国人民解放军军事医学科学院毒物药物研究所 | Novel dihydropyridine compound and application thereof on preparing drugs for curing and/or preventing virus diseases |
| EP2831060B1 (en) | 2012-03-31 | 2016-05-04 | F.Hoffmann-La Roche Ag | Novel 4-methyl-dihydropyrimidines for the treatment and prophylaxis of hepatitis b virus infection |
| US9953638B2 (en) | 2012-06-28 | 2018-04-24 | Nuance Communications, Inc. | Meta-data inputs to front end processing for automatic speech recognition |
| CA2876690C (en) * | 2012-08-24 | 2020-06-09 | Sunshine Lake Pharma Co., Ltd. | Dihydropyrimidine compounds and their application in pharmaceuticals |
| CN103664925B (en) | 2012-09-07 | 2018-01-23 | 广东东阳光药业有限公司 | The Dihydropyrimidines of heteroaryl substitution and its application in medicine |
| WO2014037480A1 (en) | 2012-09-10 | 2014-03-13 | F. Hoffmann-La Roche Ag | 6-amino acid heteroaryldihydropyrimidines for the treatment and prophylaxis of hepatitis b virus infection |
| CN103664899B (en) | 2012-09-11 | 2017-06-16 | 广东东阳光药业有限公司 | The Dihydropyrimidines of heteroaryl substitution and its application in medicine |
| WO2014165128A2 (en) | 2013-03-12 | 2014-10-09 | Novira Therapeutics, Inc. | Hepatitis b antiviral agents |
| JP2016522271A (en) | 2013-03-20 | 2016-07-28 | インディアナ・ユニバーシティ・リサーチ・アンド・テクノロジー・コーポレーション | Fluorescent HAP is a diagnostic stain for HBV core in cells |
| DK2981536T3 (en) | 2013-04-03 | 2017-09-25 | Janssen Sciences Ireland Uc | N-PHENYLC CARBOXAMIDE DERIVATIVES AND THE USE THEREOF AS MEDICINES FOR THE TREATMENT OF HEPATITIS B |
| MX2015015692A (en) * | 2013-05-17 | 2016-03-04 | Hoffmann La Roche | 6-bridged heteroaryldihydropyrimidines for the treatment and prophylaxis of hepatitis b virus infection. |
| CN104650069B (en) | 2013-11-19 | 2019-04-19 | 广东东阳光药业有限公司 | 4- methyl Dihydropyrimidines and its application in drug |
| WO2015074546A1 (en) * | 2013-11-19 | 2015-05-28 | Sunshine Lake Pharma Co., Ltd. | Dihydropyrimidine compounds and their application in pharmaceuticals |
| CN104650070B (en) | 2013-11-25 | 2018-09-14 | 广东东阳光药业有限公司 | Dihydropyrimidines and its application in drug |
| WO2015078393A1 (en) | 2013-11-27 | 2015-06-04 | Sunshine Lake Pharma Co., Ltd. | Processes for preparing dihydropyrimidine derivatives and intermediates thereof |
| SG11201607332UA (en) | 2014-03-07 | 2016-10-28 | Hoffmann La Roche | Novel 6-fused heteroaryldihydropyrimidines for the treatment and prophylaxis of hepatitis b virus infection |
| KR20160133563A (en) | 2014-03-28 | 2016-11-22 | 선샤인 레이크 파르마 컴퍼니 리미티드 | Dihydropyrimidine compounds and their application in pharmaceuticals |
| CN108329308B (en) * | 2018-05-16 | 2022-11-01 | 四川科伦博泰生物医药股份有限公司 | Solid form of dihydropyrimidine compound and preparation method thereof |
-
2017
- 2017-11-09 US US16/334,237 patent/US10696669B2/en active Active
- 2017-11-09 KR KR1020197007824A patent/KR102496508B1/en active IP Right Grant
- 2017-11-09 ES ES17870982T patent/ES2901401T3/en active Active
- 2017-11-09 BR BR112019005205A patent/BR112019005205A2/en not_active Application Discontinuation
- 2017-11-09 EP EP17870982.0A patent/EP3508483B1/en active Active
- 2017-11-09 AU AU2017359773A patent/AU2017359773B2/en active Active
- 2017-11-09 MX MX2019005119A patent/MX2019005119A/en unknown
- 2017-11-09 MY MYPI2019001442A patent/MY194471A/en unknown
- 2017-11-09 WO PCT/CN2017/110123 patent/WO2018090862A1/en active Application Filing
- 2017-11-09 CA CA3037218A patent/CA3037218A1/en active Pending
- 2017-11-09 PL PL17870982T patent/PL3508483T3/en unknown
- 2017-11-09 JP JP2019513814A patent/JP7139568B2/en active Active
- 2017-11-09 CN CN201780057446.XA patent/CN109790145B/en active Active
- 2017-11-09 SG SG10202010180YA patent/SG10202010180YA/en unknown
-
2019
- 2019-03-18 PH PH12019550039A patent/PH12019550039A1/en unknown
- 2019-04-30 IL IL266345A patent/IL266345A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA3037218A1 (en) | 2018-05-24 |
| US10696669B2 (en) | 2020-06-30 |
| AU2017359773B2 (en) | 2021-05-20 |
| EP3508483B1 (en) | 2021-10-06 |
| MX2019005119A (en) | 2019-06-20 |
| CN109790145A (en) | 2019-05-21 |
| WO2018090862A1 (en) | 2018-05-24 |
| JP7139568B2 (en) | 2022-09-21 |
| PH12019550039A1 (en) | 2019-11-25 |
| JP2019535644A (en) | 2019-12-12 |
| MY194471A (en) | 2022-11-30 |
| KR20190077312A (en) | 2019-07-03 |
| EP3508483A1 (en) | 2019-07-10 |
| US20190225603A1 (en) | 2019-07-25 |
| AU2017359773A1 (en) | 2019-04-11 |
| PL3508483T3 (en) | 2022-02-07 |
| EP3508483A4 (en) | 2020-04-15 |
| IL266345A (en) | 2019-06-30 |
| KR102496508B1 (en) | 2023-02-03 |
| BR112019005205A2 (en) | 2019-06-11 |
| ES2901401T3 (en) | 2022-03-22 |
| CN109790145B (en) | 2020-09-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA201805805B (en) | Formulations and methods | |
| EP3299369A4 (en) | Pyrido-azaheterecydic compound and preparation method and use thereof | |
| HK1251547A1 (en) | Pyrimidine or pyridopyridone compound and application thereof | |
| IL259150B (en) | Pyrimidine derivative and use thereof | |
| GB201514756D0 (en) | Compound and method of use | |
| GB201513304D0 (en) | Compositions and Methods | |
| IL266345A (en) | Dihydropyrimidine compound and preparation method and use thereof | |
| ZA202104969B (en) | Compositions comprising 15-hepe and methods of using the same | |
| GB201519128D0 (en) | Solid forms and methods of preparing the same | |
| PL3398598T3 (en) | Sulfonamide derivative and preparation method and use thereof | |
| GB201608779D0 (en) | Methods and compounds | |
| GB201608776D0 (en) | Methods and compounds | |
| ZA201704743B (en) | Mangiferin-6-o-berberine salt and preparation method and use thereof | |
| HK1247136A1 (en) | Compositions comprising 15-hepe and methods of using the same | |
| IL257167A (en) | Antitussive compositions and methods | |
| GB201705626D0 (en) | Compositions and methods | |
| ZA201807665B (en) | Methods and compositions | |
| GB201715820D0 (en) | Compositions and methods | |
| GB201512996D0 (en) | Compositions and methods | |
| IL253174A0 (en) | Nanoparticles and methods for preparation thereof | |
| EP3470403A4 (en) | Novel taxoid compound and preparation method and use thereof | |
| GB2551279B (en) | Set-delayed cement compositions comprising pumice and associated methods | |
| GB2551275B (en) | Set-delayed cement compositions comprising pumice and associated methods | |
| EP3293179A4 (en) | Amide compound and the preparation method and use thereof | |
| GB201514413D0 (en) | Compositions and methods |